Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aescine Sodium for Allergic Rhinitis
NCT06709079Not yet recruiting
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of escin in allergic rhinitis (AR). Primary endpoints: Rhinoconjunctivitis Quality of Life Questionnaire at 20 days, Visual Analogue Scale at 20 days and 1 more. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
escin
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT06709079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06709079.